NetImpact Secures Option for New MDS200 License: Identify Infected Sheep and Goats, Protect Against Spread of Chronic Waste Dise

NetImpact Secures Option for New MDS200 License: Identify Infected Sheep and
Goats, Protect Against Spread of Chronic Waste Disease 


LAS VEGAS, Feb. 17  /PRNewswire-FirstCall/ -- NetImpact Holdings, Inc. (OTC Pink
Sheets: NTHD) announces the Company has secured an option for a new exclusive
license to further develop the MDS200 technology. Currently capable of testing
humans for infectious diseases, the new option allows a NetImpact team of MDS200
scientists to develop the technology to identify Chronic Wasting disease in
sheep and goats as well as Mad Cow Disease in cattle. NetImpact expects the lab
in a box to be ready to test for Mad Cow disease and shortly thereafter for
Chronic Wasting disease in 4-6 months.

Chronic Wasting disease is similar to Mad Cow disease and has been reported in
animals roaming the U.S. One percent of white tailed deer and fifteen percent of
wild mule deer tested in captive herds in Wisconsin and Colorado were found to
be infected with Chronic Wasting disease. The media and independent groups
monitoring the spread of the disease note that hunters are checking whether
animals they kill are testing positive. Hunters are concerned that eating
infected meat could develop Creutzfeldt-Jakob, a neurological disorder that
results in severe cognitive impairment and possible death. The exact cause of
the spread of the disease from infected animal to normal animal is unknown, but
it may be transmittable through their saliva, urine, feces, contaminated food
and water. The MDS200 lab in a box technology is being developed to specifically
test cattle and is expected to also identify the disease in sheep and goats,
thus protecting against its spread to humans.

NetImpact is preparing to apply to the National Institutes of Health and
Department of Defense for research and development monies to put these versions
of the lab in a box into use without delay. The Company is pursuing partnerships
with other firms and investment capital groups in the U.S., Canada, England,
Japan and Australia.

About the MDS200

The MDS200 lab in a box is a breakthrough technology for disease detection.
Currently used on solids, gases and fluids, it is capable of automatic
preparation and testing of difficult and dirty samples containing cell, protein,
nucleic acid and chemical analytes. About the size of a small suitcase, the
MDS200 is a rugged portable laboratory designed for use in remote areas with
non-existent or scarce laboratory facilities and readily carried from location
to location.Test results are available in a matter of hours, displayed on the
unit's LED, and can be sent via satellite or dial up connections to monitoring
centers. Once sample has been placed in the lab in a box the processing is
spontaneous. Operating an MDS200does not require a trained lab technician.

About NetImpact Holdings, Inc.

NetImpact Holdings, Inc. is a technology-to-market company focusing on the
installation, restructuring and management of global healthcare and medical
delivery systems. Throughacquisitions and extensive access to
international/U.S. distribution networks, NetImpact specializes in presenting
technology that will assist in the improvement of productivity, applications
development, and technology transfer in developing countries. The Company's
NetCare Division, Medical and Diagnostic Devices Division, and Neurowave
Division are moving their technologies, products and services to an awaiting
market.

Safe Harbor Statement

The statements in this release that are not historical facts are forward-
looking statements within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934. NetImpact Holdings,
Inc. intends that such forward-looking statements be subject to the safe harbors
created thereby. These forward-looking statements include predictions, estimates
and other statements that involve a number of risks and uncertainties any, or
all, of which could cause actual results to differ materially from any future
performance suggested herein. While this outlook represents NetImpact Holdings,
Inc.'s current judgment on the future direction of the business, such risks and
uncertainties may individually, or mutually, impact the matters herein
described, including but not limited to product acceptance, the economy,
competition, governmental actions, results of litigation, technological and/or
other factors, which are outside the control of NetImpact Holdings, Inc. as well
as those risks and uncertainties detailed in the Company's Security and Exchange
Commission filings.

   CONTACT
   Jerry Jennings
   Emerson Gerard Associates
   561-881-7318
   

DATASOURCE: NetImpact Holdings, Inc.



CONTACT:  Jerry Jennings, Emerson Gerard Associates, [phone], or

, for NetImpact Holdings



Web site:  http://www.netimpact.com/ 

Copyright